FAQ: Information for health professionals on pathogen-reduced platelets (PPPT)

Authors: Shuoyan Ning, MD, FRCPC, DRCPSC; Bryan Tordon, MD, FRCPC; Michelle Zeller, MD, FRCPC, DRCPSC; Waseem Anani, MD

Last updated: June 17, 2024

NOTE: This information reflects evidence available at time of publication. This information is specific to Pooled Platelet Psoralen-Treated (PPPT) components, which were fully implemented across Canadian Blood Services on May 6, 2024. See Chapter 19 of the Clinical Guide to Transfusion for more information including additional resources (slide decks, narrated videos, animations).

General

1. How do component characteristics for pathogen-reduced platelets (specifically pooled platelet psoralen-treated or PPPT) compare to untreated platelets?

See Table 1 for a comparison of component characteristics (this table is excerpted from Chapter 19 of the Clinical Guide to Transfusion).

Table 1: Component characteristics of PPPT and untreated platelets

2. What is the technology used for pathogen-reduced platelet components, and how does it work?

Canadian Blood Services uses the INTERCEPT Pathogen Inactivation Technology by Cerus to treat platelets. This technology uses a psoralen compound (amotosalen) and UV light to cause irreversible damage to genetic material present in pathogens, rendering them inactive.

3. Will pooled platelets psoralen-treated (PPPT) completely replace untreated pooled platelets?

Canadian Blood Service's platelet inventory is now entirely APPT or PPPT; however, a small inventory of apheresis platelets in PAS-E (untreated) will be available by request for limited indications.

4. Will PPPT replace untreated apheresis platelets? Will there be a change in available inventory of untreated apheresis platelets?

PPPT and apheresis platelet psoralen-treated (APPT) have been implemented by Canadian Blood Services nationally. Apheresis platelet in PAS-E (untreated) will be available by request for limited indications. Please see additional information in the FAQ on APPT and untreated apheresis platelet in PAS-E and Canadian Blood Services' Circular of Information for more information.

5. Can we order both units of PPPT originating from the same parent unit?

Yes, a paired dose can be issued to a hospital, if specifically requested and if available. Standard platelet orders will be issued by the oldest expiry, unless otherwise indicated.

6. What post-implementation data collection and analysis is taking place?

Canadian Blood Services will be monitoring for changes in platelet component demand, wastage, and inventory changes.

7. What information is Health Canada monitoring regarding the use of pathogen-reduced platelets?

Health Canada is expected to evaluate the residual leukocyte content, pH, and platelet yield, as well as sterility testing at time of expiration.

8. Do hospitals need to perform isoagglutinin titrations with the PPPT since they are suspended in a combination of PAS and plasma?

As of November 2022, Canadian Blood Services began performing automated isohemagglutinin titre testing (anti-A1 and anti-B) on all whole blood and apheresis donors. Pathogen-reduced platelets that meet the low-titre criteria will be labelled "Low Anti-A/B" (please see the FAQ on donor high titre isohemagglutinin testing for more information). For pooled platelets, all donors contributing to a platelet pool must be low titre for the component to be labelled as "Low Anti-A/B". Since PPPT platelets are manufactured from 7 donors, a minority of these platelets are expected to be labelled as low titre.

For pathogen-reduced platelet components that are not labelled as "Low Anti-A/B", Canadian Blood Services cannot make any claims about ABO titres. However, it is expected that ABO antibody concentration in PPPT will decrease compared to untreated (not pathogen-reduced) platelets due to the removal of approximately 60% of the plasma and addition of Platelet Additive Solution (PAS). Hospitals can make a segment from the sampling pouch line and use it to prepare a titration if desired.

9. Does the pathogen inactivation process and/or residual psoralen impact any laboratory investigations?

The psoralen added to the platelets is very effectively removed by a compound adsorption device at the end of the manufacturing process. The residual psoralen that may be left (trace amounts) and the pathogen inactivation process has no impact on laboratory investigations.  

10. How should an adverse reaction to pathogen-reduced platelets be reported? 

Adverse reaction reporting for pathogen-reduced platelets follows the process used to report an adverse reaction to a blood component manufactured by Canadian Blood Services. See Canadian Blood Services' Guide to reporting adverse transfusion reactions for more information (see the reporting algorithm for blood components in Figure 1). 

Components and administration

11. Will hospitals need to continue irradiating untreated (pooled or apheresis) platelets provided by Canadian Blood Services?

Untreated (pooled or apheresis) platelet components need to be irradiated as per standard practices when clinically indicated. Canadian Blood Services will continue to provide irradiated untreated platelet components to hospitals.  Pathogen reduced platelet components should not undergo irradiation and are safe to use for recipients requiring irradiated blood components.

12. What happens if a pathogen-reduced platelet gets irradiated in error? Can it still be used? 

Pathogen-reduced platelets do not require irradiation, as leukocytes are inactivated by the pathogen inactivation process. However, if a pathogen-reduced platelet is irradiated in error, it may still be transfused as per manufacturer's recommendations. 

13. What will happen to HLA and HPA matched platelets?

Pathogen reduction for both apheresis and pooled platelets was fully implemented across Canadian Blood Services on May 6, 2024.  The majority of HLA and HPA matched platelets will be pathogen inactivated. Untreated apheresis platelets in PAS-E that are HLA or HPA matched are available to order for limited indications.

Please use the Request for HLA/HPA Selected Platelets form and include requirements for apheresis in PAS (untreated) in the ‘Additional Information’ section (this includes requests for IUT platelets).

For more information, see the FAQ on APPT and untreated apheresis platelet in PAS-E.

14. Can aliquots be obtained from a PPPT unit for transfusion? What is the minimal residual volume of a PPPT unit? Can PPPT units be volume reduced (centrifuged and supernatant removed)?

Yes, aliquots can be obtained as long as a minimal residual volume of 135mL remains in the platelet bag. In other words, once there is 135mL or less remaining in the platelet bag, the platelet component can no longer be used and no further aliquots can be obtained. PPPT should not be volume reduced unless transferred to a bag suitable for centrifugation.

15. Do untreated (apheresis or pooled) platelet components have the same concentration as PPPT?

No, untreated platelet components are less concentrated than PPPT. The final concentration of the PPPT component is approximately 1.4 times more concentrated than untreated pooled platelets. Please see Table 1.

16. Is the tail on the PPPT unit long enough to allow docking to another bag?

Yes, once the bulb is removed, the remaining tubing length is approximately 8 cm. This should be sufficient for docking another bag depending on the tube welder device used.

17. Can a patient receive both untreated (apheresis platelet in PAS-E) and PPPT to meet their transfusion requirements?

Yes, patients may receive both untreated (apheresis platelets in PAS-E) platelets and PPPT to meet their transfusion requirements.

18. Can the same line be used for untreated (apheresis platelet in PAS-E) platelets and PPPT?

Yes, both PPPT and untreated (apheresis platelet in PAS-E) platelets can be hung in the same line, provided the tubing has not expired.

19. Is there a difference in infusion time with the various platelet components?

No, PPPT can be transfused at the same rate as untreated (apheresis platelet in PAS-E) platelets. The rate should follow hospital policy.

20. What do I do if I see microaggregates in psoralen-treated platelets? 

Microaggregates have been reported in some units. Aggregates should dissipate following agitation. Placing units in landscape orientation on agitator may help reduce aggregate formation. Platelets containing visible particles are not inferior to particle-free concentrates.¹ 

Clinical use

21. Is premedication required before receiving a PPPT unit?

Premedication is not specifically required for transfusion of PPPT components.

22. What is the adult dose of a PPPT component compared with other platelet components?

For adults, a PPPT component will be equivalent to an untreated (pooled or apheresis) platelet component.

23. What is the neonatal and pediatric dosing for PPPT and untreated platelets?

For both PPPT and untreated platelet components the recommended doses for pediatric and neonatal platelet transfusions are provided in the Canadian Blood Services Circular of Information.

24. Can PPPT components be administered to infants undergoing phototherapy?

PPPT are not indicated for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm or have a lower bound of the emission bandwidth less than 375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. Phototherapy in the blue-green light with peak wavelength of 450-460 nm is the current standard of care for treatment of neonatal hyperbilirubinemia in Canada.²

25. Can PPPT be administered to patients undergoing extracorporeal photopheresis (ECP) or PUVA light therapy?

There is a theoretical risk of white blood cell inactivation following transfusion of large platelet volumes combined with ECP or PUVA – if patient is exposed to the wavelength ranges with peak energy wavelength less than 425 nm or have a lower bound of the emission bandwidth less than 375 nm. There are no published case reports of harm.

26. Is the count increment expected to be similar following a dose of PPPT compared to untreated platelets?

The current evidence suggests that absolute count increments (ACI) and corrected count increment (CCI) are lower for PPPT components compared with untreated platelets. For 24 hour ACI, mean difference in published studies are -4.1 (95% CI -7.16 to -1.04) and -8.3 (95% CI -9.82 to -6.06) in single and multiple platelet transfusion studies, respectively. There were no differences in bleeding outcomes, and only 7% of hematology oncology patients transfused with pathogen-reduced platelets required additional platelet transfusions compared to patients transfused with untreated platelets.³

27. Will the increased number of donors in PPPT increase HLA alloimmunization?

No, the current evidence does not suggest an increased risk of HLA alloimmunization. There are conflicting data regarding alloimmunization rates due to the varying preparations of pathogen-reduced platelets and technologies deployed in clinical trials. Overall, there appears to be no change in alloimmunization rate with INTERCEPT platelets.⁴

28. What do I do if my patient has a psoralen allergy? (including psoralen food allergies)

There is no published data on the safety of transfusing pathogen-reduced platelets to patients with psoralen allergies, including psoralen food allergies. Hemovigilance data has shown a reduced risk of allergic reactions among patients receiving pathogen-reduced platelets compared to untreated platelet components overall. While the compound adsorption device removes amotosalen leaving trace amounts in the product, there is a theoretical risk of allergic/anaphylactic transfusion reactions if patients with psoralen allergies are transfused with pathogen-reduced platelets.

For patients with psoralen allergies, a request for non-pathogen reduced platelets can be made through Canadian Blood Services but requires a minimum of 3 days to fill the order (see additional information in the FAQ on apheresis platelet psoralen-treated and untreated apheresis platelet in PAS-E). In emergency situations, the risks and benefits of transfusion should be assessed on an individual basis and considerations for interventions such as pre-medication can be made. 

References

1. Feys B, D.R., De Pourcq K, et al. Apheresis platelet concentrates containing visible particles are not inferior to particle-free concentrates, in vitro. Vox sanguinis 105(Suppl. 1), 11 (2013). 

2. Barrington KJ, S.K., Canadian Paediatric Society, Fetus and Newborn Committee. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) - Summary. Paediatr Child Health 12, 401-418 (2007). 

3. Estcourt, L.J., Malouf, R., Hopewell, S., et al. Pathogen‐reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews 30(2017). 

4. McCullough, J., Vesole, D.H., Benjamin, R.J., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 104, 1534-1541 (2004).